A statement of changes in beneficial ownership was filed on September 15, 2026, disclosing a transaction by Brent Pfeiffenberger, President and CEO of Century Therapeutics, Inc., involving common stock on September 11, 2026.

Key Highlights

  • Reporting person: Brent Pfeiffenberger, President and CEO and Director of Century Therapeutics, Inc.
  • Transaction type: 13,850 shares of common stock were disposed of (transaction code F) on September 11, 2026, at a price of $1.94 per share.
  • Purpose of disposal: According to the filing, the shares were "withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units."
  • Remaining ownership: Following the transaction, Pfeiffenberger directly beneficially owned 3,633,839 shares of common stock.
  • Issuer and listing: Century Therapeutics, Inc. trades on NASDAQ:IPSC.

CEO Share Withholding at Century Therapeutics Upon RSU Vesting

Century Therapeutics, Inc., a biopharmaceutical company listed on NASDAQ:IPSC, was the subject of this beneficial ownership filing. The filing covers a single transaction involving the company's President and CEO, Brent Pfeiffenberger, who is identified in the filing as both a Director and an Officer of the issuer.

According to the filing, 13,850 shares of Century Therapeutics common stock were disposed of on September 11, 2026, under transaction code F, at a per-share price of $1.94. The filing explains that these shares represent amounts "withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units." This type of transaction, coded F, reflects shares surrendered directly to the company rather than sold on the open market, and is a common mechanism used to cover tax liabilities triggered by RSU vesting events.

Following this disposal, Pfeiffenberger's direct beneficial ownership in Century Therapeutics common stock stood at 3,633,839 shares, as reported in the filing. No derivative securities transactions were reported in Table II of the filing. The statement was filed on September 15, 2026, and was signed by Douglas Carr as attorney-in-fact on behalf of the reporting person.

What Was Disclosed

The filing disclosed that Century Therapeutics CEO Brent Pfeiffenberger had 13,850 shares of common stock withheld at $1.94 per share on September 11, 2026, to cover tax obligations upon RSU vesting, leaving him with direct beneficial ownership of 3,633,839 shares.